ClinicalTrials.Veeva

Menu

Effects of Intraoperative Esmolol on Post-mastectomy Pain Syndrome

H

Hospital de Base

Status

Unknown

Conditions

Post-mastectomy Pain Syndrome

Treatments

Drug: Esmolol
Drug: Control

Study type

Observational

Funder types

Other

Identifiers

NCT03965442
Post-mastectomy pain

Details and patient eligibility

About

Chronic postoperative pain is an entity that is usually neglected by anesthetists, but several studies show that the choice of anesthetic technique may interfere with this prevalence. Esmolol is a selective beta-blocker of ultra fast duration that has been studied as a perioperative venous adjuvant with antihyperalgesic and opioid sparing action. The investigators ventured the possibility of this anti-hyperalgesic effect attenuating the chronic pain syndrome post-mastectomy.

Enrollment

66 estimated patients

Sex

Female

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients previously submitted to the study Analgesic Effect of Intraoperative Esmolol in Mastectomies: a randomized placebo controlled trial

Exclusion criteria

  • Patient aged less than 18 years and over 65 years;
  • Patients who refuse to participate in the study;
  • Patients with pulmonary disease;
  • Patients with cardiac, renal or hepatic disease;
  • Use of psychoactive drug;
  • Patients with sinus bradycardia;
  • Pregnant women;
  • Patients with allergy to dipyrone, morphine;
  • Patients with chronic pain prior to the surgical procedure;
  • Patients with neurological disorders;
  • Patients undergoing surgical resurfacing

Trial design

66 participants in 2 patient groups

Control
Description:
Patients who underwent mastectomy under standard general anesthesia Patients in placebo group received general balanced inhaled anesthesia with sevoflurane and remifentanil and a saline 0,9% infusion pump.
Treatment:
Drug: Control
Esmolol
Description:
Patients in esmolol group received general balanced inhaled anesthesia with sevoflurane and a bolus infection of esmolol 500 mgc/kg followed by a continuous infusion of esmolol 100 mcg/kg/min
Treatment:
Drug: Esmolol

Trial contacts and locations

1

Loading...

Central trial contact

Fabricio T Mendonça, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems